ENOblock is a small molecule inhibitor that targets the enzyme enolase, particularly the alpha-enolase isoform, which plays a role in glycolysis and has been implicated in various disease processes. It has drawn significant interest for its potential therapeutic applications in cancer and inflammatory conditions. In cancer research, ENOblock has shown the ability to suppress tumor cell proliferation and induce apoptosis in certain cancer cell lines by disrupting glycolytic activity and downregulating key oncogenic signaling pathways. It may also inhibit cancer cell migration and invasion, suggesting a role in limiting metastasis. Additionally, ENOblock has been explored for its anti-inflammatory properties. By modulating enolase activity outside of its metabolic function—such as when it is expressed on the surface of immune or stressed cells—ENOback may interfere with inflammatory responses and autoimmunity. Due to these actions, ENOblock serves as a research tool in studying metabolic reprogramming in diseases and is being investigated for its potential in developing targeted therapies, especially in cancers reliant on aerobic glycolysis (the Warburg effect) and in conditions involving abnormal immune activation.